[
  {
    "date": "2022-12-31",
    "symbol": "ASND",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "December 31, 2022",
    "documentfiscalyearfocus": 2022,
    "documentfiscalperiodfocus": "FY",
    "tradingsymbol": "ASND",
    "entityregistrantname": "Ascendis Pharma A/S",
    "entitycentralindexkey": 1612042,
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "Yes",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Large accelerated filer",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "true",
    "entitycommonstocksharesoutstanding": "null",
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "entityincorporationstatecountrycode": "The Kingdom of Denmark",
    "entityaddresscountry": "Denmark",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "documentregistrationstatement": "false",
    "security12btitle": "Ordinary shares",
    "securityexchangename": "The Nasdaq Stock Market LLC",
    "entityaddressaddressline1": "Tuborg Boulevard 12",
    "entityaddresscityortown": "Hellerup",
    "contactpersonnelname": "Jan MÃ¸ller Mikkelsen",
    "cityareacode": 45,
    "localphonenumber": "70 22 22 44",
    "entityfilenumber": "001-36815",
    "notradingsymbolflag": "true",
    "icfrauditorattestationflag": "true",
    "auditorname": "Deloitte Statsautoriseret Revisionspartnerselskab",
    "auditorfirmid": 1294,
    "auditorlocation": "Copenhagen, Denmark",
    "entityaddresspostalzipcode": "DK-2900",
    "revenue": 6466000,
    "costofsales": 12137000,
    "grossprofit": 39037000,
    "researchanddevelopmentexpense": 379624000,
    "sellinggeneralandadministrativeexpense": 221227000,
    "profitlossfromoperatingactivities": -561814000,
    "shareofprofitlossofassociatesaccountedforusingequitymethod": -17697000,
    "financeincome": 52181000,
    "financecosts": 50487000,
    "profitlossbeforetax": -577817000,
    "incometaxexpensecontinuingoperations": 5377000,
    "profitloss": -583194000,
    "profitlossattributabletoownersofparent": -583194000,
    "basicanddilutedearningslosspershares": -10.4,
    "weightedaverageshares": "null",
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": -327000,
    "othercomprehensiveincomethatwillbereclassifiedtoprofitorlossnetoftax": -327000,
    "comprehensiveincome": -40273000,
    "comprehensiveincomeattributabletoownersofparent": -583521000,
    "dilutiveeffectofconvertibleinstrumentsonnumberofordinaryshares": "null",
    "potentialconversionofconvertibleseniornotesintonumberofordinaryshares": "null",
    "goodwillandotherintangibleassets": 4828000,
    "propertyplantandequipment": 89922000,
    "investmentsinassociates": 22932000,
    "othernoncurrentreceivables": 1920000,
    "noncurrentfinancialassetsavailableforsale": 7201000,
    "noncurrentassets": 21410000,
    "inventories": 130673000,
    "currenttradereceivables": 11910000,
    "currenttaxassetscurrent": 883000,
    "othercurrentreceivables": 12833000,
    "currentprepayments": 31717000,
    "currentfinancialassetsavailableforsale": 288642000,
    "cashandcashequivalents": 444767000,
    "currentassets": 92204000,
    "assets": 113614000,
    "issuedcapital": 7675000,
    "distributableequity": 255673000,
    "equity": 100062000,
    "longtermborrowings": 482956000,
    "noncurrentderivativefinancialliabilities": 157950000,
    "noncurrentcontractliabilities": 14213000,
    "noncurrentliabilities": 180000,
    "shorttermborrowings": 25421000,
    "tradeandothercurrentpayablestotradesuppliers": 101032000,
    "othercurrentliabilities": 31989000,
    "currenttaxliabilities": 5490000,
    "currentprovisions": 7339000,
    "currentliabilities": 13372000,
    "liabilities": 826390000,
    "equityandliabilities": 113614000,
    "increasedecreasethroughsharebasedpaymenttransactions": 64180000,
    "purchaseoftreasuryshares": 106099000,
    "saleorissueoftreasuryshares": -6000,
    "increasedecreasethroughtransactionswithowners": 5153000,
    "reversalofgainlossonpropertyplantandequipment": 22000,
    "adjustmentsforprovisions": 6145000,
    "adjustmentsfornoncashconsiderationregardingrevenue": 2547000,
    "adjustmentsforsharebasedpayments": 64180000,
    "adjustmentsfordepreciationexpense": 17514000,
    "adjustmentsforamortisationexpense": 444000,
    "adjustmentsfordecreaseincreaseininventories": -55268000,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": -11531000,
    "adjustmentsfordecreaseincreaseinprepaidexpenses": -6409000,
    "adjustmentsforincreasedecreaseindeferredincomeotherthancontractliabilities": 8648000,
    "adjustmentsforincreasedecreaseintradeandotherpayables": 45943000,
    "cashflowsfromusedinoperations": -494673000,
    "financeincomereceivedclassifiedasoperatingactivities": 8271000,
    "financecostspaidclassifiedasoperatingactivities": 9294000,
    "incometaxespaidrefundclassifiedasoperatingactivities": 3000,
    "cashflowsfromusedinoperatingactivities": -495699000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 14489000,
    "reimbursementfromacquisitionofpropertyplantandequipment": 9535000,
    "purchaseofavailableforsalefinancialassets": 213842000,
    "proceedsfromdisposalormaturityofavailableforsalefinancialassets": 280528000,
    "cashflowsfromusedininvestingactivities": 61732000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 6356000,
    "netproceedsfromconvertibleseniornotes": -503281000,
    "proceedsfromexerciseofwarrants": 5153000,
    "paymentstoacquireorredeementitysshares": 105305000,
    "cashflowsfromusedinfinancingactivities": 396773000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": -37194000,
    "effectofexchangeratechangesoncashandcashequivalents": 35694000,
    "shorttermdepositsclassifiedascashequivalents": 427810000,
    "shortterminvestmentsclassifiedascashequivalents": 16957000,
    "treasuryshares": 149000,
    "parvaluepershare": 0.13,
    "convertibleseniornotes": 545161000,
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": 11,
    "otherprovisions": 7300000,
    "projectcostprepaymentscurrent": 4400000,
    "projectcostaccrualscurrent": 38000000,
    "warrantcompensationcost": 55200000,
    "derivativefinancialliabilities": 157950000,
    "revenuefromsaleofgoods": 35659000,
    "revenuefromrenderingofservices": 4434000,
    "revenuefromsaleofclinicalsupply": 8534000,
    "licencefeeincome": 2547000,
    "numberofreportableoperatingsegments": 1,
    "noncurrentassetsotherthanfinancialinstrumentsdeferredtaxassetspostemploymentbenefitassetsandrightsarisingunderinsurancecontracts": 133923000,
    "wagesandsalaries": 6087000,
    "expensefromsharebasedpaymenttransactionswithemployees": 8872000,
    "postemploymentbenefitexpensedefinedbenefitplans": 118000,
    "socialsecuritycontributions": 89000,
    "employeebenefitsexpense": 15166000,
    "averagenumberofemployees": 719,
    "numberofemployees1": 4,
    "numberofinstrumentsotherequityinstrumentsgranted": 347082,
    "numberofadditionalsharesgranted": "null",
    "exercisepriceofoutstandingshareoptions2019": 145.5,
    "weightedaverageremainingcontractuallifeofoutstandingotherequityinstruments": 77,
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": "null",
    "numberofotherequityinstrumentstransferredinsharebasedpaymentarrangement": 41685,
    "numberofotherequityinstrumentsforfeitedinsharebasedpaymentarrangement": 363541,
    "numberofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement": 214613,
    "numberofotherequityinstrumentsvestedinsharebasedpaymentarrangement": "null",
    "weightedaverageexercisepriceofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement2019": 81.3,
    "weightedaverageexercisepriceofotherequityinstrumentsgrantedinsharebasedpaymentarrangement2019": 100.56,
    "weightedaverageexercisepriceofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement2019": 21.83,
    "weightedaverageexercisepriceofotherequityinstrumentsforfeitedinsharebasedpaymentarrangement2019": 123.62,
    "weightedaverageexercisepriceofotherequityinstrumentsvestedinsharebasedpaymentarrangement": 66.34,
    "weightedaverageshareprice2019": 113.6,
    "yearofgrantofwarrants": 2022,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.4924,
    "descriptionsofriskfreeinterestrateshareoptionsgranted": 0.025400000000000002,
    "descriptionofoptionlifeshareoptionsgranted": 6,
    "weightedaverageexercisepriceofotherequityinstrumentsexercisableinsharebasedpaymentarrangement2019": 100.4,
    "fairvalueofwarrantsgranted": 60.85,
    "auditorsremunerationforauditservices": 814000,
    "auditorsremunerationfortaxservices": 138000,
    "auditorsremuneration": 952000,
    "currenttaxexpenseincome": -5377000,
    "currenttaxexpenseincomeandadjustmentsforcurrenttaxofpriorperiods": -5377000,
    "accountingprofit": -577817000,
    "taxexpenseincomeatapplicabletaxrate": 127120000,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 17094000,
    "taxeffectofdeductibleitemsnotexpensed": 13720000,
    "taxeffectsfromimpactsfromassociates": 3893000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 2716000,
    "taxeffectfromdeferredtaxassetnotrecognized": -122514000,
    "averageeffectivetaxrate": -0.009300000000000001,
    "taxeffectoftaxlosses": 433174000,
    "othertemporarydifferencesbeforevaluationallowances": 19961000,
    "deferredtaxassetnotrecognized": -453135000,
    "applicabletaxrate": 0.22,
    "incometaxespaidrefund": -700000,
    "taxlossescarryforwards": 1985000000,
    "additionaltaxdeduction": 5200000,
    "intangibleassetsandgoodwill": 4828000,
    "amortisationintangibleassetsotherthangoodwill": -444000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 14803000,
    "depreciationpropertyplantandequipment": 17514000,
    "disposalspropertyplantandequipment": -5885000,
    "increasedecreasethroughnetexchangedifferencespropertyplantandequipment": -1098000,
    "proportionofownershipinterestinassociate": 0.4393,
    "profitlossfortheyear": -40283000,
    "saleofgoodsandservicestoassociate": 22327000,
    "tradereceivables": 11910000,
    "shareofequitybeforeeliminations": 43957000,
    "eliminationofinternalprofitrecognized": 21025000,
    "shareofequityaftereliminations": 22932000,
    "currentrawmaterialsandcurrentproductionsupplies": 9616000,
    "workinprogress": 112885000,
    "finishedgoods": 8172000,
    "inventoriestotal": 130673000,
    "leaseextensionperiod": "five years",
    "leaseliabilities": 109191000,
    "interestexpenseonleaseliabilities": 3842000,
    "depreciationrightofuseassets": 11740000,
    "expenserelatingtoshorttermleasesforwhichrecognitionexemptionhasbeenused": 280000,
    "leaseexpenses": 15862000,
    "revenuerecognizedfromcontractliabilities": 10500000,
    "notionalamount": 1000,
    "borrowingsinterestrate": 0.0225,
    "borrowingsinarrearsdefaultpaymentstartdate": "October 1, 2022",
    "conversionratepernote": 6.0118,
    "conversionpricepershare": 166.34,
    "borrowingsredemptionperiod": "April 7, 2025",
    "borrowingsconditionforredemption": "but only if the last reported sale price per ADS exceeds 130% of the conversion price on each of (i) at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related optional redemption notice; and (ii) the trading day immediately before the date the Company sends such notice. ",
    "borrowingsthresholdpercentageofsalepricepershareforredemption": 1.3,
    "borrowingsthresholdtradingdaysforredemption": 20,
    "borrowingsthresholdconsecutivetradingdaysforredemption": 30,
    "percentageofreasonablypossibleincreaseinunobservableinputliabilities": 0.1,
    "increasedecreaseinderivativefinancialliabilitiesfairvalue": 142467000,
    "otherreceivables": 3884000,
    "marketablesecuritiesexplanatory": 295843000,
    "financialassetsatamortisedcost": 295843000,
    "financialassets": 93795000,
    "noncurrentfinancialassets": 9412000,
    "currentfinancialassets": 749329000,
    "tradeandotherpayablestotradesuppliers": 101032000,
    "financialliabilitiesatamortisedcost": 382459000,
    "financialliabilitiesatfairvaluethroughprofitorloss": 157950000,
    "financialliabilities": 606107000,
    "noncurrentfinancialliabilities": 640907000,
    "currentfinancialliabilities": 126452000,
    "revenuefrominterest": 7426000,
    "netforeignexchangegain": 44755000,
    "interestexpense": 30682000,
    "lossesonchangeinfairvalueofderivatives": 15483000,
    "otherfinancecost": 4322000,
    "liabilitiesarisingfromfinancingactivities": 508377000,
    "increasedecreasethrougheffectofrepaymentsliabilitiesarisingfromfinancingactivities": -14705000,
    "increasedecreasethrougheffectofproceedsliabilitiesarisingfromfinancingactivities": -503281000,
    "increasedecreasethroughfinancingcashflowsliabilitiesarisingfromfinancingactivities": 3194000,
    "increasedecreasethroughchangesinfairvaluesliabilitiesarisingfromfinancingactivities": -142467000,
    "increasedecreasethrougheffectofaccretionofinterestliabilitiesarisingfromfinancingactivities": 34058000,
    "increasedecreasethrougheffectofchangesinforeignexchangeratesliabilitiesarisingfromfinancingactivities": 20055000,
    "derivativefinancialliabilitiesatfairvalueremeasurementrecognizedinfinancialincomeorexpense": 15483000,
    "numberofsharesissued": "null",
    "increasedecreasethroughcashcontribution": 214613,
    "weightedaveragedurationofmarketablesecuritiescurrentexplanatory": 3,
    "weightedaveragedurationofmarketablesecuritiesnoncurrentexplanatory": 12.6,
    "weightedaveragedurationofmarketablesecuritiesexplanatory": 3.2,
    "realizeddurationoffinancialassetsexplanatory": "twelve months",
    "purchaseoftreasurysharesnominalvalue": 134000,
    "treasurysharestransferredunderstockincentiveprogramnominalvalue": -6000,
    "numberoftreasurysharesoutstanding": "null",
    "increasedecreaseintreasurysharesacquiredfromthirdparties": "null",
    "increasedecreaseintreasurysharestransferredunderstockincentiveprogram": -41685,
    "treasurysharesholdinginpercentageoftotaloutstandingshares": 0.02,
    "nominalvalueamount": 60581000,
    "increasedecreaseinforeigncurrencyexchangerate": 0.1,
    "gainslossesonchangeinvalueofforeigncurrencybasisspreadsbeforetax": 6058000,
    "financialassetsavailableforsale": 295843000,
    "borrowings": 508377000,
    "tradeandotherpayables": 101032000,
    "nonderivativefinancialliabilitiesundiscountedcashflows": 609409000,
    "contractualundiscountedcashflowoffinancialleaseliabilities": 128763000,
    "contractualundiscountedcashflowofconvertibleseniornotes": 605810000,
    "contractualundiscountedcashflowofborrowings": 734573000,
    "contractualundiscountedcashflowoftradepayablesandotherpayables": 101032000,
    "contractualundiscountedcashflowoffinancialliabilities": 835605000,
    "contractualcapitalcommitments": 4400000,
    "nameofsubsidiary": "Ascendis Pharma Oncology Division A/S",
    "countryofincorporationorresidenceofsubsidiary": "Denmark",
    "proportionofownershipinterestinsubsidiary": 1,
    "nameofassociate": "VISEN Pharmaceuticals",
    "countryofincorporationorresidenceofassociate": "Cayman Island",
    "minimumbeneficialownershippercentage": 0.05,
    "majorpersonsorgroupsofaffiliatedpersonsholdingminimumbeneficialownership": "Entities affiliated with Janus Henderson Group plc, United Kingdom"
  },
  {
    "date": "2021-12-31",
    "symbol": "ASND",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2021-12-31",
    "documentfiscalyearfocus": 2021,
    "documentfiscalperiodfocus": "FY",
    "tradingsymbol": "ASND",
    "entityregistrantname": "Ascendis Pharma A/S",
    "entitycentralindexkey": 1612042,
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "Yes",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Large Accelerated Filer",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "entitycommonstocksharesoutstanding": 56937682,
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "entityincorporationstatecountrycode": "G7",
    "entityaddresscountry": "DK",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "documentregistrationstatement": "false",
    "security12btitle": "American Depositary Shares",
    "securityexchangename": "NASDAQ",
    "entityaddressaddressline1": "Tuborg Boulevard 12",
    "entityaddresscityortown": "Hellerup",
    "contactpersonnelname": "Jan MÃ¸ller Mikkelsen",
    "cityareacode": 45,
    "localphonenumber": "70 22 22 44",
    "entityfilenumber": "001-36815",
    "notradingsymbolflag": "true",
    "icfrauditorattestationflag": "true",
    "auditorname": "Deloitte Statsautoriseret Revisionspartnerselskab",
    "auditorfirmid": 1294,
    "auditorlocation": "Copenhagen, Denmark",
    "entityaddresspostalzipcode": "DK-2900",
    "revenue": 7778000,
    "costofsales": 3523000,
    "grossprofit": 4255000,
    "researchanddevelopmentexpense": 295867000,
    "sellinggeneralandadministrativeexpense": 160180000,
    "profitlossfromoperatingactivities": -451792000,
    "shareofprofitlossofassociatesaccountedforusingequitymethod": 12041000,
    "financeincome": 59718000,
    "financecosts": 3911000,
    "profitlossbeforetax": -383944000,
    "incometaxexpensecontinuingoperations": -367000,
    "profitloss": -383577000,
    "profitlossattributabletoownersofparent": -383577000,
    "basicanddilutedearningslosspershares": -7,
    "weightedaverageshares": 54771763,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": 3855000,
    "othercomprehensiveincomethatwillbereclassifiedtoprofitorlossnetoftax": 3855000,
    "comprehensiveincome": -379722000,
    "comprehensiveincomeattributabletoownersofparent": -379722000,
    "dilutiveeffectofconvertibleinstrumentsonnumberofordinaryshares": 7085073,
    "goodwillandotherintangibleassets": 5272000,
    "propertyplantandequipment": 126049000,
    "investmentsinassociates": 38345000,
    "othernoncurrentreceivables": 1808000,
    "noncurrentfinancialassetsavailableforsale": 107561000,
    "noncurrentassets": 279035000,
    "inventories": 75405000,
    "currenttradereceivables": 2200000,
    "currenttaxassetscurrent": 893000,
    "othercurrentreceivables": 20093000,
    "currentprepayments": 25231000,
    "currentfinancialassetsavailableforsale": 235797000,
    "cashandcashequivalents": 446267000,
    "currentassets": 805886000,
    "assets": 1084921000,
    "issuedcapital": 7646000,
    "distributableequity": 875989000,
    "equity": 883635000,
    "noncurrentleaseliabilities": 97966000,
    "noncurrentcontractliabilities": 2964000,
    "noncurrentliabilities": 100930000,
    "currentleaseliabilities": 6995000,
    "currentcontractliabilities": 2601000,
    "tradeandothercurrentpayablestotradesuppliers": 59417000,
    "othercurrentliabilities": 29952000,
    "currenttaxliabilities": 198000,
    "currentprovisions": 1193000,
    "currentliabilities": 100356000,
    "liabilities": 201286000,
    "equityandliabilities": 1084921000,
    "increasedecreasethroughsharebasedpaymenttransactions": 66830000,
    "purchaseoftreasuryshares": 21605000,
    "increasedecreasethroughtransactionswithowners": 429000,
    "costsofcapitalincreasedecrease": 19974000,
    "adjustmentsforprovisions": 1193000,
    "adjustmentsfornoncashconsiderationregardingrevenue": 2365000,
    "adjustmentsforsharebasedpayments": 66830000,
    "adjustmentsfordepreciationexpense": 14946000,
    "adjustmentsforamortisationexpense": 445000,
    "adjustmentsfordecreaseincreaseininventories": -75405000,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": -6659000,
    "adjustmentsfordecreaseincreaseinprepaidexpenses": -11238000,
    "adjustmentsforincreasedecreaseindeferredincomeotherthancontractliabilities": 5202000,
    "adjustmentsforincreasedecreaseintradeandotherpayables": 39186000,
    "cashflowsfromusedinoperations": -419657000,
    "financeincomereceivedclassifiedasoperatingactivities": 3697000,
    "financecostspaidclassifiedasoperatingactivities": 1841000,
    "incometaxespaidrefundclassifiedasoperatingactivities": -152000,
    "cashflowsfromusedinoperatingactivities": -417649000,
    "purchaseofinterestsinassociates": 10187000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 23704000,
    "paymentsfordevelopmentprojectexpenditure": 530000,
    "purchaseofavailableforsalefinancialassets": 226038000,
    "proceedsfromdisposalormaturityofavailableforsalefinancialassets": 149880000,
    "cashflowsfromusedininvestingactivities": -110579000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 6429000,
    "proceedsfromexerciseofwarrants": 11537000,
    "proceedsfromissuingshares": 367884000,
    "paymentstoacquireorredeementitysshares": 21605000,
    "cashflowsfromusedinfinancingactivities": 351387000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": -176841000,
    "effectofexchangeratechangesoncashandcashequivalents": 38591000,
    "shorttermdepositsclassifiedascashequivalents": 441736000,
    "shortterminvestmentsclassifiedascashequivalents": 4531000,
    "parvaluepershare": 1,
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": "P5Y",
    "numberoflicenses": 3,
    "additionalleaseperiodinadditontononcancellableperiod": "P5Y",
    "projectcostprepaymentscurrent": 8000000,
    "projectcostaccrualscurrent": 23500000,
    "warrantcompensationcost": 66100000,
    "upfrontpaymentreceivednoncashconsiderationtowardslicenserevenue": 40000000,
    "proportionofownershipinterestinassociate": 0.5,
    "revenuefromsaleofgoods": 943000,
    "revenuefromrenderingofservices": 751000,
    "revenuefromsaleofclinicalsupply": 3719000,
    "licencefeeincome": 2365000,
    "deferredrevenuefromassociate": 2400000,
    "percentageofentitysrevenue": 0.95,
    "numberofreportableoperatingsegments": 1,
    "noncurrentassetsotherthanfinancialinstrumentsdeferredtaxassetspostemploymentbenefitassetsandrightsarisingunderinsurancecontracts": 29656000,
    "wagesandsalaries": 104583000,
    "expensefromsharebasedpaymenttransactionswithemployees": 66830000,
    "postemploymentbenefitexpensedefinedbenefitplans": 2416000,
    "socialsecuritycontributions": 4571000,
    "employeebenefitsexpense": 178400000,
    "averagenumberofemployees": 573,
    "numberofemployees1": 6,
    "exercisepriceofoutstandingshareoptions2019": 6.48,
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 148148,
    "numberofinstrumentsotherequityinstrumentsgranted": 148148,
    "numberofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement": 312296,
    "numberofotherequityinstrumentsforfeitedinsharebasedpaymentarrangement": 196616,
    "numberofotherequityinstrumentsvestedinsharebasedpaymentarrangement": 4022011,
    "weightedaverageexercisepriceofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement2019": 123.46,
    "weightedaverageexercisepriceofotherequityinstrumentsgrantedinsharebasedpaymentarrangement2019": 123.46,
    "weightedaverageexercisepriceofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement2019": 38.43,
    "weightedaverageexercisepriceofotherequityinstrumentsforfeitedinsharebasedpaymentarrangement2019": 119.58,
    "weightedaverageexercisepriceofotherequityinstrumentsvestedinsharebasedpaymentarrangement": 52.63,
    "weightedaverageshareprice2019": 124.62,
    "yearofgrantofwarrants": "2012-2017",
    "weightedaverageremainingcontractuallifeofoutstandingotherequityinstruments": "P53M",
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.48,
    "descriptionsofriskfreeinterestrateshareoptionsgranted": -0.0054,
    "descriptionofoptionlifeshareoptionsgranted": 6,
    "weightedaverageexercisepriceofotherequityinstrumentsexercisableinsharebasedpaymentarrangement2019": 122.03,
    "fairvalueofwarrantsgranted": 45.91,
    "percentageofwarrantsvested": 0.25,
    "numberofadditionalsharesgranted": 1316588,
    "sharebasedpaymentarrangementvestingperiod": "P48M",
    "auditorsremunerationforauditservices": 771000,
    "auditorsremunerationfortaxservices": 87000,
    "auditorsremunerationforotherservices": 13000,
    "auditorsremuneration": 871000,
    "currenttaxexpenseincome": 367000,
    "currenttaxexpenseincomeandadjustmentsforcurrenttaxofpriorperiods": 367000,
    "accountingprofit": -383944000,
    "taxexpenseincomeatapplicabletaxrate": 84468000,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 14800000,
    "taxeffectofdeductibleitemsnotexpensed": 17117000,
    "taxeffectsfromimpactsfromassociates": 3169000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 305000,
    "taxeffectfromdeferredtaxassetnotrecognized": -89892000,
    "averageeffectivetaxrate": -0.001,
    "taxeffectoftaxlosses": 313011000,
    "othertemporarydifferencesbeforevaluationallowances": 12856000,
    "deferredtaxassetnotrecognized": -325867000,
    "applicabletaxrate": 0.22,
    "incometaxespaidrefund": -700000,
    "taxlossescarryforwards": 1437000000,
    "additionaltaxdeduction": 4800000,
    "intangibleassetsandgoodwill": 3495000,
    "amortisationintangibleassetsotherthangoodwill": -445000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 2810000,
    "depreciationpropertyplantandequipment": 1499000,
    "disposalspropertyplantandequipment": 772000,
    "increasedecreasethroughnetexchangedifferencespropertyplantandequipment": 286000,
    "constructioninprogress": 1900,
    "constructionexpenditureincurredbutnotpaid": 2100,
    "considerationpaidreceived": 40000000,
    "proportionofvotingpowerheldinassociate": 0.4393,
    "principalplaceofbusinessofassociate": "China",
    "profitlossfortheyear": -69283000,
    "saleofgoodsandservicestoassociate": 6472000,
    "tradereceivables": 1644000,
    "contractliabilities": 5565000,
    "shareofequitybeforeeliminations": 59455000,
    "eliminationofinternalprofitrecognized": 21110000,
    "shareofequityaftereliminations": 38345000,
    "currentrawmaterialsandcurrentproductionsupplies": 2248000,
    "workinprogress": 68865000,
    "finishedgoods": 4292000,
    "inventoriestotal": 75405000,
    "reversalofinventorywritedown": 53700000,
    "leaseextensionperiod": "P5Y",
    "leaseterm": "P11Y",
    "enforceableleaseterm": "P4Y",
    "leasecommenceperiod": "January 2022",
    "leaseliabilities": 2300000,
    "cashoutflowforleases": 6429000,
    "interestpaidclassifiedasfinancingactivities": 1326000,
    "additionstoleaseliabilities": 10812000,
    "interestexpenseonleaseliabilities": 3396000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 6533000,
    "depreciationrightofuseassets": 10963000,
    "expenserelatingtoshorttermleasesforwhichrecognitionexemptionhasbeenused": 186000,
    "leaseexpenses": 14545000,
    "transactionpriceallocatedtoremainingperformanceobligations": 2600000,
    "revenuerecognizedfromcontractliabilities": 400000,
    "contractualcapitalcommitments": 8400000,
    "otherreceivables": 12276000,
    "marketablesecuritiesexplanatory": 343358000,
    "financialassetsatamortisedcost": 804101000,
    "tradeandotherpayablestotradesuppliers": 59417000,
    "financialliabilitiesatamortisedcost": 164378000,
    "revenuefrominterest": 692000,
    "netforeignexchangegain": 59026000,
    "interestexpense": 3911000,
    "numberofsharesissued": 56937682,
    "increasedecreasethroughcashcontribution": 3187296,
    "foreigncurrencytargetpercentage": 0.045,
    "weightedaveragedurationofmarketablesecuritiescurrentexplanatory": "P5M24D",
    "weightedaveragedurationofmarketablesecuritiesnoncurrentexplanatory": "P16M21D",
    "weightedaveragedurationofmarketablesecuritiesexplanatory": "P9M6D",
    "realizeddurationoffinancialassetsexplanatory": "P12M",
    "treasuryshares": 21000,
    "purchaseoftreasurysharesnominalvalue": 21000,
    "numberoftreasurysharesoutstanding": 154837,
    "increasedecreaseintreasurysharesacquiredfromthirdparties": 154837,
    "treasurysharesholdinginpercentageoftotaloutstandingshares": 0.003,
    "nominalvalueamount": 549243000,
    "increasedecreaseinforeigncurrencyexchangerate": 0.1,
    "gainslossesonchangeinvalueofforeigncurrencybasisspreadsbeforetax": 54924000,
    "financialassets": 323176000,
    "financialassetsavailableforsale": 343358000,
    "tradeandotherpayables": 59417000,
    "financialliabilities": 66515000,
    "contractualundiscountedcashflowoffinancialleaseliabilities": 126918000,
    "contractualundiscountedcashflowoftradepayablesandotherpayables": 59417000,
    "contractualundiscountedcashflowoffinancialliabilities": 186335000,
    "nameofsubsidiary": "Ascendis Pharma GmbH",
    "countryofincorporationorresidenceofsubsidiary": "Germany",
    "proportionofownershipinterestinsubsidiary": 1,
    "nameofassociate": "VISEN Pharmaceuticals",
    "countryofincorporationorresidenceofassociate": "Cayman Island",
    "minimumbeneficialownershippercentage": 0.05,
    "majorpersonsorgroupsofaffiliatedpersonsholdingminimumbeneficialownership": "T. Rowe Price Associates, Inc., USA"
  },
  {
    "date": "2020-12-31",
    "symbol": "ASND",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2020-12-31",
    "documentfiscalyearfocus": 2020,
    "documentfiscalperiodfocus": "FY",
    "tradingsymbol": "ASND",
    "entityregistrantname": "Ascendis Pharma A/S",
    "entitycentralindexkey": 1612042,
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "Yes",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Large Accelerated Filer",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "entitycommonstocksharesoutstanding": 53750386,
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "entityincorporationstatecountrycode": "G7",
    "entityaddresscountry": "DK",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "documentregistrationstatement": "false",
    "security12btitle": "Ordinary shares",
    "securityexchangename": "NASDAQ",
    "contactpersonnelname": "Jan M&#248;ller Mikkelsen",
    "cityareacode": 45,
    "localphonenumber": "70 22 22 44",
    "entityfilenumber": "001-36815",
    "notradingsymbolflag": "true",
    "icfrauditorattestationflag": "true",
    "revenue": 73000,
    "researchanddevelopmentexpense": 260904000,
    "sellinggeneralandadministrativeexpense": 76669000,
    "profitlossfromoperatingactivities": -330620000,
    "shareofprofitlossofassociatesaccountedforusingequitymethod": -9524000,
    "financeincome": 1812000,
    "financecosts": 80842000,
    "profitlossbeforetax": -419174000,
    "incometaxexpensecontinuingoperations": -219000,
    "profitloss": -418955000,
    "profitlossattributabletoownersofparent": -418955000,
    "basicanddilutedearningslosspershare": -8.28,
    "weightedaverageshares": 50616528,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": -42000,
    "othercomprehensiveincomethatwillbereclassifiedtoprofitorlossnetoftax": -42000,
    "comprehensiveincome": -19049000,
    "comprehensiveincomeattributabletoownersofparent": -418997000,
    "dilutiveeffectofconvertibleinstrumentsonnumberofordinaryshares": 6148004,
    "goodwillandotherintangibleassets": 5717000,
    "propertyplantandequipment": 9841000,
    "investmentsinassociates": 9176000,
    "othernoncurrentreceivables": 1375000,
    "noncurrentfinancialassetsavailableforsale": 115277000,
    "noncurrentassets": 239660000,
    "currenttradereceivables": 387000,
    "othercurrentreceivables": 6957000,
    "currentprepayments": 13994000,
    "currentfinancialassetsavailableforsale": 134253000,
    "cashandcashequivalents": 584517000,
    "currentassets": 20373000,
    "assets": 37008000,
    "issuedcapital": 7217000,
    "distributableequity": 831494000,
    "equity": 33708000,
    "noncurrentleaseliabilities": 85116000,
    "othernoncurrentliabilities": 3162000,
    "noncurrentliabilities": 88278000,
    "currentleaseliabilities": 6859000,
    "currentcontractliabilities": 363000,
    "tradeandothercurrentpayablestotradesuppliers": 21897000,
    "othercurrentliabilities": 23384000,
    "currenttaxliabilities": 301000,
    "currentliabilities": 3148000,
    "liabilities": 141082000,
    "equityandliabilities": 37008000,
    "increasedecreasethroughsharebasedpaymenttransactions": 53170000,
    "increasedecreasethroughtransactionswithowners": 638797000,
    "costsofcapitalincreasedecrease": 31373000,
    "adjustmentsfornoncashconsiderationregardingrevenue": 3499000,
    "adjustmentsforsharebasedpayments": 53170000,
    "adjustmentsfordepreciationexpense": 9448000,
    "adjustmentfordecreaseincreaseintradereceivablesotherreceivablesandothershorttermdeposits": -1996000,
    "adjustmentsforincreasedecreaseinprepayments": -6357000,
    "adjustmentsforincreasedecreaseindeferredincome": -495000,
    "adjustmentsforincreasedecreaseintradeandotherpayables": 7884000,
    "cashflowsfromusedinoperations": -272465000,
    "financeincomereceivedclassifiedasoperatingactivities": 1326000,
    "financecostspaidclassifiedasoperatingactivities": 1504000,
    "incometaxespaidrefundclassifiedasoperatingactivities": -1095000,
    "cashflowsfromusedinoperatingactivities": -271548000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 19860000,
    "reimbursementfromacquisitionofpropertyplantandequipment": 5054000,
    "paymentsfordevelopmentprojectexpenditure": 1692000,
    "purchaseofavailableforsalefinancialassets": 537752000,
    "proceedsfromdisposalormaturityofavailableforsalefinancialassets": 263051000,
    "cashflowsfromusedininvestingactivities": -291199000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 4774000,
    "proceedsfromissuingshares": 638797000,
    "paymentsforshareissuecosts": 31373000,
    "cashflowsfromusedinfinancingactivities": 602650000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": 39903000,
    "effectofexchangeratechangesoncashandcashequivalents": -53492000,
    "cashdeposits": 581872000,
    "shorttermmarketablesecurities": 2645000,
    "parvaluepershare": 1,
    "numberofreportableoperatingsegments": 1,
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": "P11Y",
    "numberoflicenses": 3,
    "additionalleaseperiodinadditontononcancellableperiod": "P10Y",
    "projectcostprepaymentscurrent": 10500000,
    "projectcostaccrualscurrent": 17000000,
    "warrantcompensationcost": 53200000,
    "upfrontpaymentreceivednoncashconsiderationtowardslicenserevenue": 40000000,
    "proportionofownershipinterestinassociate": 0.5,
    "revenuefromrenderingofservices": 2140000,
    "revenuefromsaleofclinicalsupply": 2206000,
    "licencefeeincome": 2607000,
    "deferredrevenuefromassociate": 3500000,
    "noncurrentassetsotherthanfinancialinstrumentsdeferredtaxassetspostemploymentbenefitassetsandrightsarisingunderinsurancecontracts": 113829000,
    "researchanddevelopmentemployeecostsexpense": 92468000,
    "researchanddevelopmentdepreciationexpense": 7311000,
    "researchanddevelopmentexternalcostsexpense": 161125000,
    "wagesandsalaries": 2622000,
    "expensefromsharebasedpaymenttransactionswithemployees": 8272000,
    "postemploymentbenefitexpensedefinedbenefitplans": 943000,
    "socialsecuritycontributions": 100000,
    "employeebenefitsexpense": 44377000,
    "averagenumberofemployees": 410,
    "numberofemployees1": 2,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 10864718,
    "aggregatenumberofotherequityinstrumentscancelledinsharebasedpaymentarrangement": 19580,
    "numberofshareoptionsexercisedinsharebasedpaymentarrangement": 4176645,
    "numberofshareoptionsexpiredinsharebasedpaymentarrangement": 2168,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 518321,
    "numberofinstrumentsauthorisedinsharebasedpaymentarrangement": 762569,
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "Warrants granted generally vest over 48 months with 1/48 of the warrants vesting per month from the date of grant.",
    "sharebasedpaymentarrangementvestingperiod": "P24M",
    "numberofannualexcercisedperiod": 4,
    "warrantexcercisedperiod": "P21D",
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 6148004,
    "minimumpercentageofsharecapitalforequitytransctions": 0.5,
    "paymentofdividendfromequitymaximumpercentage": 0.1,
    "exercisepriceofoutstandingshareoptions2019": 145.5,
    "weightedaverageremainingcontractuallifeofoutstandingotherequityinstruments": "P94M",
    "numberofinstrumentsotherequityinstrumentsgranted": 6148004,
    "numberofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement": 905395,
    "numberofotherequityinstrumentsforfeitedinsharebasedpaymentarrangement": 252743,
    "numberofotherequityinstrumentsvestedinsharebasedpaymentarrangement": 3044827,
    "weightedaverageexercisepriceofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement2019": 69.97,
    "weightedaverageexercisepriceofotherequityinstrumentsgrantedinsharebasedpaymentarrangement2019": 54.56,
    "weightedaverageexercisepriceofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement2019": 30.56,
    "weightedaverageexercisepriceofotherequityinstrumentsforfeitedinsharebasedpaymentarrangement2019": 64.99,
    "weightedaverageexercisepriceofotherequityinstrumentsvestedinsharebasedpaymentarrangement": 37.29,
    "weightedaverageshareprice2019": 128.32,
    "yearofgrantofwarrants": 2018,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.55,
    "descriptionsofriskfreeinterestrateshareoptionsgranted": -0.0032,
    "descriptionofoptionlifeshareoptionsgranted": 7.1,
    "weightedaverageexercisepriceofotherequityinstrumentsexercisableinsharebasedpaymentarrangement2019": 137.57,
    "fairvalueofwarrantsgranted": 75.77,
    "auditorsremunerationforauditservices": 599000,
    "auditorsremunerationfortaxservices": 104000,
    "auditorsremunerationforotherservices": 22000,
    "auditorsremuneration": 725000,
    "revenuefrominterest": 1812000,
    "interestexpense": 1918000,
    "netforeignexchangeloss": 78924000,
    "currenttaxexpenseincome": 219000,
    "currenttaxexpenseincomeandadjustmentsforcurrenttaxofpriorperiods": 219000,
    "accountingprofit": -419174000,
    "taxexpenseincomeatapplicabletaxrate": 92218000,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 11815000,
    "taxeffectofdeductibleitemsnotexpensed": 24564000,
    "taxeffectsfromimpactsfromassociates": -1326000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 2673000,
    "taxeffectfromdeferredtaxassetnotrecognized": -106095000,
    "averageeffectivetaxrate": -0.0005,
    "taxeffectoftaxlosses": 227234000,
    "othertemporarydifferencesbeforevaluationallowances": 7726000,
    "deferredtaxassetnotrecognized": -234960000,
    "applicabletaxrate": 0.22,
    "incometaxespaidrefund": -700000,
    "taxlossescarryforwards": 1043800000,
    "additionaltaxdeduction": 16300000,
    "intangibleassetsandgoodwill": 5717000,
    "additionsotherthanthroughbusinesscombinationsintangibleassetsotherthangoodwill": 2222000,
    "unpaidadditionsotherthanthroughbusinesscombinationsintangibleassetsotherthangoodwill": 500000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 7169000,
    "depreciationpropertyplantandequipment": 9448000,
    "disposalspropertyplantandequipment": 221000,
    "increasedecreasethroughnetexchangedifferencespropertyplantandequipment": 580000,
    "constructioninprogress": 2300000,
    "constructionexpenditureincurredbutnotpaid": 1000000,
    "considerationpaidreceived": 40000000,
    "revenuefromassociate": 200000,
    "principalplaceofbusinessofassociate": "China",
    "profitlossfortheyear": -19049000,
    "shareofequitybeforeeliminations": 16854000,
    "eliminationofinternalprofitrecognized": 7678000,
    "shareofequityaftereliminations": 9176000,
    "longtermdeposits": 1375000,
    "incometaxreceivables": 778000,
    "valueaddedtaxreceivables": 5276000,
    "miscellaneousotherreceivables": 903000,
    "otherreceivables": 2251000,
    "numberofsharesissued": 53750386,
    "increasedecreasethroughcashcontribution": 5764549,
    "leaseextensionperiod": "P10Y",
    "leaseterm": "P11Y",
    "rightofuseassets": 64600000,
    "leasetermenforceableyear": 2029,
    "leaseterminate": 2026,
    "leaseliabilities": 91975000,
    "additionstoleaseliabilities": 64582000,
    "interestexpenseonleaseliabilities": 1617000,
    "cashoutflowforleases": 5990000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -4853000,
    "depreciationrightofuseassets": 1972000,
    "expenserelatingtoshorttermleasesforwhichrecognitionexemptionhasbeenused": 470000,
    "leaseexpenses": 8944000,
    "deferredincome": 400000,
    "revenuerecognizedfromdeferredincome": 1000000,
    "contractualcapitalcommitments": 15800000,
    "tradereceivables": 387000,
    "marketablesecuritiesexplanatory": 249558000,
    "financialassetsatamortisedcost": 836713000,
    "tradeandotherpayablestotradesuppliers": 21897000,
    "financialliabilitiesatamortisedcost": 113872000,
    "foreigncurrencytargetpercentage": 0.045,
    "weightedaveragedurationofmarketablesecuritiescurrentexplanatory": "P6Y",
    "weightedaveragedurationofmarketablesecuritiesnoncurrentexplanatory": "P17Y3M18D",
    "weightedaveragedurationofmarketablesecuritiesexplanatory": "P11Y2M12D",
    "realizeddurationoffinancialassetsexplanatory": "P0M",
    "currentassetsliabilities": 797900,
    "proceedsfromcommonstockandmarketablesecurities": 797900,
    "financialassetsavailableforsale": 249530000,
    "financialassets": 56826000,
    "nominalvalueamount": 797927000,
    "increasedecreaseinforeigncurrencyexchangerate": 0.1,
    "gainslossesonchangeinvalueofforeigncurrencybasisspreadsbeforetax": 79793000,
    "tradeandotherpayables": 21897000,
    "financialliabilities": 113872000,
    "contractualundiscountedcashflowoffinancialleaseliabilities": 113811000,
    "contractualundiscountedcashflowoftradepayablesandotherpayables": 21897000,
    "contractualundiscountedcashflowoffinancialliabilities": 135708000,
    "nameofsubsidiary": "Ascendis Pharma Oncology Division A/S",
    "countryofincorporationorresidenceofsubsidiary": "USA",
    "proportionofownershipinterestinsubsidiary": 1,
    "nameofassociate": "VISEN Pharmaceuticals",
    "countryofincorporationorresidenceofassociate": "Cayman Island",
    "minimumbeneficialownershippercentage": 0.05,
    "majorpersonsorgroupsofaffiliatedpersonsholdingminimumbeneficialownership": "Entities affiliated with Janus Henderson Group plc, United Kingdom"
  },
  {
    "date": "2019-12-31",
    "symbol": "ASND",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2019-12-31",
    "documentfiscalyearfocus": 2019,
    "documentfiscalperiodfocus": "FY",
    "tradingsymbol": "ASND",
    "entityregistrantname": "Ascendis Pharma A/S",
    "entitycentralindexkey": 1612042,
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "Yes",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Large Accelerated Filer",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "entitycommonstocksharesoutstanding": 47985837,
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "entityincorporationstatecountrycode": "G7",
    "entityaddresscountry": "DK",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "documentregistrationstatement": "false",
    "security12btitle": "Ordinary shares",
    "securityexchangename": "NASDAQ",
    "contactpersonnelname": "Jan M&#248;ller Mikkelsen",
    "cityareacode": 45,
    "localphonenumber": "70 22 22 44",
    "entityfilenumber": "001-36815",
    "notradingsymbolflag": "true",
    "revenue": 10723000,
    "researchanddevelopmentexpense": 191621000,
    "sellinggeneralandadministrativeexpense": 48473000,
    "profitlossfromoperatingactivities": -226719000,
    "shareofprofitlossofassociatesaccountedforusingequitymethod": -8113000,
    "financeincome": 17803000,
    "financecosts": 1221000,
    "profitlossbeforetax": -218250000,
    "incometaxexpensecontinuingoperations": -234000,
    "profitloss": 11372000,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": -37000,
    "othercomprehensiveincomethatwillbereclassifiedtoprofitorlossnetoftax": -37000,
    "comprehensiveincome": -218053000,
    "comprehensiveincomeattributabletoownersofparent": -218053000,
    "basicanddilutedearningslosspershare": -4.69,
    "weightedaverageshares": 46506862,
    "dilutiveeffectofconvertibleinstrumentsonnumberofordinaryshares": 5820211,
    "goodwill": 3495000,
    "propertyplantandequipment": 34891000,
    "investmentsinassociates": 15538000,
    "longtermdeposits": 1463000,
    "noncurrentassets": 23291000,
    "receivablefromassociate": 804000,
    "othercurrentreceivables": 3136000,
    "currentprepayments": 7648000,
    "currenttaxassetscurrent": 1473000,
    "cashandcashequivalents": 598106000,
    "currentassets": 32446000,
    "assets": 676732000,
    "issuedcapital": 6443000,
    "distributableequity": 590671000,
    "equity": 53820000,
    "noncurrentleaseliabilities": 30720000,
    "othernoncurrentpayables": 908000,
    "noncurrentliabilities": 250000,
    "currentleaseliabilities": 5899000,
    "currentcontractliabilities": 858000,
    "tradeandothercurrentpayablestotradesuppliers": 27765000,
    "othercurrentpayables": 13349000,
    "currenttaxliabilities": 119000,
    "currentliabilities": 1667000,
    "liabilities": 79618000,
    "equityandliabilities": 676732000,
    "othercomprehensiveincome": -37000,
    "increasedecreasethroughsharebasedpaymenttransactions": 37486000,
    "increasedecreasethroughtransactionswithowners": 529332000,
    "costsofcapitalincreasedecrease": 31701000,
    "noncashconsideration": 6522000,
    "adjustmentsforsharebasedpayments": 37486000,
    "adjustmentsfordepreciationexpense": 6689000,
    "adjustmentsforincreasedecreaseinoperatingleasedeposits": -305000,
    "adjustmentsfordecreaseincreaseinreceivables": -1877000,
    "adjustmentsforincreasedecreaseinprepayments": 4766000,
    "adjustmentsforincreasedecreaseintradeandotherpayables": 7530000,
    "adjustmentsforincreasedecreaseindeferredincome": -6044000,
    "cashflowsfromusedinoperations": -184996000,
    "financeincomereceivedclassifiedasoperatingactivities": 10056000,
    "financecostspaidclassifiedasoperatingactivities": 717000,
    "incometaxespaidrefundclassifiedasoperatingactivities": 279000,
    "cashflowsfromusedinoperatingactivities": -175936000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 5159000,
    "cashflowsfromusedininvestingactivities": -5159000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 4038000,
    "proceedsfromissuingshares": 529332000,
    "paymentsforshareissuecosts": 31701000,
    "cashflowsfromusedinfinancingactivities": 493593000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": 312498000,
    "effectofexchangeratechangesoncashandcashequivalents": 7746000,
    "restrictedcashandcashequivalents": 5776000,
    "parvaluepershare": 0.13,
    "numberofreportableoperatingsegments": 1,
    "leaseliabilities": 36619000,
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": "P10Y",
    "numberofcollaborationagreements": 2,
    "numberoflicenses": 3,
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "Effective from January 2015, certain warrants issued to board members vest over 24 months with 1/24 of the warrants vesting per month from the date of grant.",
    "numberoftranches": 48,
    "additionalleaseperiodinadditontononcancellableperiod": "P6Y",
    "weightedaveragelesseesincrementalborrowingrateappliedtoleaseliabilitiesrecognisedatdateofinitialapplicationofifrs16": 0.05,
    "projectcostprepaymentscurrent": 5800000,
    "projectcostaccrualscurrent": 10500000,
    "revenuefromrenderingofservices": 9919000,
    "revenuefromsaleofclinicalsupply": 804000,
    "licencefeeincome": 2652000,
    "revenuefromcontractswithcustomers": 13400000,
    "noncurrentassetsotherthanfinancialinstrumentsdeferredtaxassetspostemploymentbenefitassetsandrightsarisingunderinsurancecontracts": 48564000,
    "wagesandsalaries": 2080000,
    "expensefromsharebasedpaymenttransactionswithemployees": 1864000,
    "postemploymentbenefitexpensedefinedbenefitplans": 648000,
    "socialsecuritycontributions": 94000,
    "employeebenefitsexpense": 7212000,
    "averagenumberofemployees": 274,
    "numberofemployees1": 2,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 9378787,
    "aggregatenumberofotherequityinstrumentscancelledinsharebasedpaymentarrangement": 19580,
    "numberofshareoptionsexercisedinsharebasedpaymentarrangement": 3271250,
    "numberofshareoptionsexpiredinsharebasedpaymentarrangement": 2168,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 265578,
    "numberofinstrumentsauthorisedinsharebasedpaymentarrangement": 1237525,
    "sharebasedpaymentarrangementvestingperiod": "P24M",
    "numberofannualexcercisedperiod": 4,
    "warrantexcercisedperiod": "P21D",
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 5232726,
    "minimumpercentageofsharecapitalforequitytransctions": 0.5,
    "paymentofdividendfromequitymaximumpercentage": 0.1,
    "exercisepriceofoutstandingshareoptions2019": 107.14,
    "weightedaverageremainingcontractuallifeofoutstandingotherequityinstruments": "P94M",
    "numberofinstrumentsotherequityinstrumentsgranted": 1290400,
    "numberofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement": 1058722,
    "numberofotherequityinstrumentsforfeitedinsharebasedpaymentarrangement": 33296,
    "numberofotherequityinstrumentsvestedinsharebasedpaymentarrangement": 2705693,
    "weightedaverageexercisepriceofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement2019": 46.36,
    "weightedaverageexercisepriceofotherequityinstrumentsgrantedinsharebasedpaymentarrangement2019": 97.01,
    "weightedaverageexercisepriceofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement2019": 16.33,
    "weightedaverageexercisepriceofotherequityinstrumentsforfeitedinsharebasedpaymentarrangement2019": 58.49,
    "weightedaverageexercisepriceofotherequityinstrumentsvestedinsharebasedpaymentarrangement": 24.93,
    "weightedaverageshareprice2019": 108.54,
    "yearofgrantofwarrants": 2019,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.54,
    "descriptionsofriskfreeinterestrateshareoptionsgranted": -0.0077,
    "descriptionofoptionlifeshareoptionsgranted": 7.1,
    "weightedaverageexercisepriceofotherequityinstrumentsexercisableinsharebasedpaymentarrangement2019": 97.01,
    "fairvalueofwarrantsgranted": 55640,
    "revenuefrominterest": 10056000,
    "netforeignexchangegain": 7747000,
    "interestexpense": 207000,
    "interestexpenseonleaseliabilities": 1014000,
    "currenttaxexpenseincome": 234000,
    "currenttaxexpenseincomeandadjustmentsforcurrenttaxofpriorperiods": 234000,
    "accountingprofit": -218250000,
    "taxexpenseincomeatapplicabletaxrate": 48015000,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 8249000,
    "taxeffectofdeductibleitemsnotexpensed": 10875000,
    "taxeffectsfromimpactsfromassociates": -1680000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 1602000,
    "taxeffectfromdeferredtaxassetnotrecognized": -50329000,
    "averageeffectivetaxrate": -0.0011,
    "taxeffectoftaxlosses": 123234000,
    "othertemporarydifferencesbeforevaluationallowances": 5631000,
    "deferredtaxassetnotrecognized": -128865000,
    "applicabletaxrate": 0.22,
    "incometaxespaidrefund": -700000,
    "taxlossescarryforwards": 560200000,
    "increasedecreaseinpropertyplantandequipmentduetoadoptionofnewleasepolicy": 18437000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 28535000,
    "depreciationpropertyplantandequipment": 6688000,
    "disposalspropertyplantandequipment": -154000,
    "increasedecreasethroughnetexchangedifferencespropertyplantandequipment": 4000,
    "propertyplantandequipmentexpendituresrecognisedforconstructions": 2700000,
    "leaseholdsimprovementspayable": 2100000,
    "additionstorightofuseassets": 39000000,
    "proportionofownershipinterestinassociate": 0.5,
    "considerationpaidreceived": 40000000,
    "revenuefromassociate": 13400000,
    "receivablesduefromassociates": 800000,
    "principalplaceofbusinessofassociate": "China",
    "profitlossfortheyear": -16226000,
    "shareofequitybeforeeliminations": 26910000,
    "shareofequityaftereliminations": 15538000,
    "numberofsharesissued": 47985837,
    "increasedecreasethroughcashcontribution": 5850389,
    "leaseextensionperiod": "P6Y",
    "leaseterm": "P10Y",
    "cashoutflowforleasesincludeprepaidleases": 4500000,
    "additionstoleaseliabilities": 21240000,
    "cashoutflowforleases": 3870000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 535000,
    "depreciationrightofuseassets": 1294000,
    "expenserelatingtoshorttermleasesforwhichrecognitionexemptionhasbeenused": 202000,
    "leaseexpenses": 6453000,
    "deferredincome": 900000,
    "revenuerecognizedfromdeferredincome": 6100000,
    "contractualcapitalcommitments": 8500000,
    "tradereceivables": 804000,
    "financialassetsatamortisedcost": 600373000,
    "tradeandotherpayablestotradesuppliers": 27765000,
    "financialliabilitiesatamortisedcost": 64384000,
    "foreigncurrencytargetpercentage": 0.045,
    "increasedecreaseinforeigncurrencyexchangerate": 0.1,
    "percentageofincreasedecreaseinsensitivityanalysis": 0.1,
    "nominalvalueamount": -858000,
    "gainslossesonchangeinvalueofforeigncurrencybasisspreadsbeforetax": -86000,
    "tradeandotherpayables": 27765000,
    "financialliabilities": 64384000,
    "contractualundiscountedcashflowoffinancialleaseliabilities": 43031000,
    "contractualundiscountedcashflowoftradepayablesandotherpayables": 27765000,
    "contractualundiscountedcashflowoffinancialliabilities": 70796000,
    "nameofsubsidiary": "Ascendis Pharma Oncology Division A/S",
    "countryofincorporationorresidenceofsubsidiary": "Denmark",
    "proportionofownershipinterestinsubsidiary": 1,
    "nameofassociate": "Visen Pharmaceuticals",
    "countryofincorporationorresidenceofassociate": "Cayman&#160;Island",
    "minimumbeneficialownershippercentage": 0.05,
    "descriptionofnatureofrelatedpartyrelationship": "investors, or groups of affiliated investors, are known by us to beneficially own more than 5% of our outstanding ordinary shares",
    "majorpersonsorgroupsofaffiliatedpersonsholdingminimumbeneficialownership": "Baker Bros. Advisors LP, USA",
    "descriptionofamericandepositoryshares": "The Company&#8217;s American Depository Shares are held through BNY (Nominees) Limited as nominee, of The Bank of New York Mellon, UK (as registered holder of the Company&#8217;s outstanding ADSs)."
  },
  {
    "date": "2018-12-31",
    "symbol": "ASND",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2018-12-31",
    "documentfiscalyearfocus": 2018,
    "documentfiscalperiodfocus": "FY",
    "tradingsymbol": "ASND",
    "entityregistrantname": "Ascendis Pharma A/S",
    "entitycentralindexkey": 1612042,
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "Yes",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Large Accelerated Filer",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "entitycommonstocksharesoutstanding": 42135448,
    "revenue": 10500000,
    "researchanddevelopmentexpense": 140281000,
    "sellinggeneralandadministrativeexpense": 25057000,
    "profitlossfromoperatingactivities": -154757000,
    "shareofprofitlossofassociatesaccountedforusingequitymethod": -321000,
    "financeincome": 24714000,
    "financecosts": 127000,
    "profitlossbeforetax": -130491000,
    "incometaxexpensecontinuingoperations": -394000,
    "profitloss": -130097000,
    "othercomprehensiveincomenetoftaxexchangedifferencesontranslation": 17000,
    "othercomprehensiveincomethatwillbereclassifiedtoprofitorlossnetoftax": 17000,
    "comprehensiveincome": 17000,
    "comprehensiveincomeattributabletoownersofparent": -130080000,
    "basicanddilutedearningslosspershare": -3.17,
    "weightedaverageshares": 41085237,
    "dilutiveeffectofconvertibleinstrumentsonnumberofordinaryshares": 5611629,
    "goodwill": 3495000,
    "propertyplantandequipment": 2197000,
    "investmentsinassociates": 17083000,
    "longtermdeposits": 1158000,
    "noncurrentassets": 34819000,
    "currenttradereceivables": 6000,
    "othercurrentreceivables": 1775000,
    "currentprepayments": 12415000,
    "currenttaxassetscurrent": 849000,
    "cashandcashequivalents": 277862000,
    "currentassets": 34155000,
    "assets": 318968000,
    "issuedcapital": 5659000,
    "distributableequity": 274391000,
    "equity": 68965000,
    "currentcontractliabilities": 6902000,
    "tradeandothercurrentpayablestotradesuppliers": 19740000,
    "othercurrentpayables": 12267000,
    "currenttaxliabilities": 9000,
    "currentliabilities": 9000,
    "liabilities": 38918000,
    "equityandliabilities": 318968000,
    "othercomprehensiveincome": 17000,
    "increasedecreasethroughsharebasedpaymenttransactions": 19652000,
    "increasedecreasethroughtransactionswithowners": 215693000,
    "costsofcapitalincreasedecrease": 13118000,
    "noncashconsideration": 10508000,
    "adjustmentsforsharebasedpayments": 19652000,
    "adjustmentsfordepreciationexpense": 880000,
    "adjustmentsforincreasedecreaseinoperatingleasedeposits": -865000,
    "adjustmentsfordecreaseincreaseintradeaccountreceivable": 182000,
    "adjustmentsfordecreaseincreaseinotheroperatingreceivables": -365000,
    "adjustmentsforincreasedecreaseinprepayments": -5508000,
    "adjustmentsforincreasedecreaseintradeandotherpayables": 8262000,
    "cashflowsfromusedinoperations": -143027000,
    "financeincomereceivedclassifiedasoperatingactivities": 4020000,
    "financecostspaidclassifiedasoperatingactivities": 127000,
    "incometaxespaidrefundclassifiedasoperatingactivities": -332000,
    "cashflowsfromusedinoperatingactivities": -138802000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 2648000,
    "cashflowsfromusedininvestingactivities": -2648000,
    "proceedsfromissuingshares": 216385000,
    "paymentsforshareissuecosts": 13118000,
    "cashflowsfromusedinfinancingactivities": 203267000,
    "increasedecreaseincashandcashequivalentsbeforeeffectofexchangeratechanges": 61817000,
    "effectofexchangeratechangesoncashandcashequivalents": 20694000,
    "restrictedcashandcashequivalents": 5566000,
    "parvaluepershare": 0.13,
    "otherpayablesterm": "P1Y",
    "numberofreportableoperatingsegments": 1,
    "rightofuseassets": 18000000,
    "leaseliabilities": 17400000,
    "usefullivesordepreciationratespropertyplantandequipment": "5 Years",
    "numberofcollaborationagreements": 2,
    "numberoflicenses": 3,
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "Up to 48 months",
    "numberoftranches": 48,
    "revenuefromrenderingofservices": 1215000,
    "licencefeeincome": 10500000,
    "numberofcustomers": 1,
    "wagesandsalaries": 1809000,
    "expensefromsharebasedpaymenttransactionswithemployees": 9427000,
    "postemploymentbenefitexpensedefinedbenefitplans": 444000,
    "socialsecuritycontributions": 152000,
    "employeebenefitsexpense": 17161000,
    "averagenumberofemployees": 167,
    "numberofemployees1": 7,
    "aggregatenumberofotherequityinstrumentscancelledinsharebasedpaymentarrangement": 19580,
    "numberofinstrumentsauthorisedinsharebasedpaymentarrangement": 2538125,
    "sharebasedpaymentarrangementvestingperiod": "P48M",
    "numberofannualexcercisedperiod": 4,
    "aggregatenumberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 657749,
    "warrantexcercisedperiod": "P21D",
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 5611629,
    "minimumpercentageofsharecapitalforequitytransctions": 0.5,
    "paymentofdividendfromequitymaximumpercentage": 0.1,
    "bonusissuanceofsharesratio": 3,
    "bonussharesissuancewarrantsadjustmentratio": 3,
    "bonussharesissuancewarrantsexercisepriceadjustmentratio": 3,
    "exercisepriceofoutstandingshareoptions": 60.23,
    "weightedaverageremainingcontractuallifeofoutstandingotherequityinstruments": 118,
    "numberofinstrumentsotherequityinstrumentsgranted": 1633375,
    "numberofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement": 611683,
    "numberofotherequityinstrumentsforfeitedinsharebasedpaymentarrangement": 35217,
    "numberofotherequityinstrumentsvestedinsharebasedpaymentarrangement": 2478770,
    "weightedaverageexercisepriceofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 58.01,
    "weightedaverageexercisepriceofotherequityinstrumentsgrantedinsharebasedpaymentarrangement": 54.43,
    "weightedaverageexercisepriceofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement": 10.82,
    "weightedaverageexercisepriceofotherequityinstrumentsforfeitedinsharebasedpaymentarrangement": 28.24,
    "weightedaverageexercisepriceofotherequityinstrumentsvestedinsharebasedpaymentarrangement": 15.81,
    "yearofgrantofwarrants": 2018,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.57,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0046,
    "descriptionofoptionlifeshareoptionsgranted": 7.14,
    "weightedaverageexercisepriceofotherequityinstrumentsexercisableinsharebasedpaymentarrangement": 54.43,
    "fairvalueofwarrantsgranted": 31.81,
    "revenuefrominterest": 4020000,
    "netforeignexchangegain": 20694000,
    "interestexpense": 127000,
    "currenttaxexpenseincome": 394000,
    "currenttaxexpenseincomeandadjustmentsforcurrenttaxofpriorperiods": 394000,
    "accountingprofit": -130491000,
    "taxexpenseincomeatapplicabletaxrate": 28708000,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 4327000,
    "taxeffectofdeductibleitemsnotexpensed": 4074000,
    "taxeffectofshareofprofitlossofassociates": -71000,
    "unrecognizeddeferredtaxfromassociates": -2312000,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 143000,
    "taxeffectfromvaluationadjustmentsondeferredtaxassets": -25821000,
    "averageeffectivetaxrate": -0.003,
    "taxeffectoftaxlosses": -74120000,
    "deferredtaxexpenseincome": -3092000,
    "othertemporarydifferencesbeforevaluationallowances": -1324000,
    "deferredtaxassetvaluationallowance": 78536000,
    "applicabletaxrate": 0.22,
    "incometaxespaidrefund": -700000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 1206000,
    "depreciationpropertyplantandequipment": 53000,
    "disposalspropertyplantandequipment": 68000,
    "propertyplantandequipmentexpendituresrecognisedforconstructions": 222000,
    "nameofsubsidiary": "Ascendis Pharma Ophthalmology Division A/S",
    "countryofincorporationorresidenceofsubsidiary": "Denmark",
    "proportionofownershipinterestinsubsidiary": 1,
    "nameofassociate": "VISEN Pharmaceuticals",
    "countryofincorporationorresidenceofassociate": "Cayman Island",
    "proportionofownershipinterestinassociate": 0.5,
    "considerationpaidreceived": 40000000,
    "considerationpaidreceivedinshares": 40000000,
    "contractliabilities": 6900000,
    "tradereceivables": 6000,
    "principalplaceofbusinessofassociate": "Cayman Island",
    "profitlossfortheyear": -642000,
    "shareofequitybeforeeliminations": 34483000,
    "shareofequityaftereliminations": 17083000,
    "numberofsharesissued": 42135448,
    "increasedecreasethroughcashcontribution": 5151156,
    "deferredincome": 6900000,
    "minimumleasepaymentspayableundernoncancellableoperatinglease": 4220000,
    "rentalexpense": 2700000,
    "financialassetsatamortisedcost": 279026000,
    "tradeandotherpayablestotradesuppliers": 19740000,
    "financialliabilitiesatamortisedcost": 19740000,
    "foreigncurrencytargetpercentage": 0.045,
    "increasedecreaseinforeigncurrencyexchangerate": 0.1,
    "percentageofincreasedecreaseinsensitivityanalysis": 0.1,
    "nominalvalueamount": -816000,
    "gainslossesonchangeinvalueofforeigncurrencybasisspreadsbeforetax": -82000,
    "minimumbeneficialownershippercentage": 0.05,
    "descriptionofnatureofrelatedpartyrelationship": "Persons, or groups of affiliated persons, are known by us to  beneficially own more than 5% of our outstanding ordinary shares",
    "majorpersonsorgroupsofaffiliatedpersonsholdingminimumbeneficialownership": "Entities affiliated with Vivo Capital, USA",
    "descriptionofamericandepositoryshares": "The Company's American Depository Shares are held through BNY (Nominees) Limited  as nominee, of The Bank of New York Mellon, UK (as registered holder of the  Company's outstanding ADSs)."
  }
]